A Study in Adult Subjects With Chronic Hepatitis B Infection to Support the Development of Immunological Assays
調査の概要
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
-
Brussels、ベルギー、1070
- GSK Investigational Site
-
Bruxelles、ベルギー、1000
- GSK Investigational Site
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Written informed consent obtained from the subject.
- Subjects who the investigator believes that they can and will comply with the requirements of the protocol.
- A male or female between, and including, 18 and 65 years of age at study start.
- Evidence of chronic hepatitis B infection as per medical record.
- Female subjects of non-childbearing potential may be enrolled in the study.
- Female subjects of childbearing potential may be enrolled in the study, if the subject has practiced adequate contraception for 30 day prior to study start.
In addition to these general inclusion criteria, subjects should satisfy ALL specific criteria according to the specified group maximum 6 months prior to Visit 1 as per medical records:
Group A: Immune tolerant patients
- Viral load: > 2x107 IU/mL of HBV DNA
- HBeAg positive
- Normal levels of ALT according to lab range Group B: HBeAg positive chronic hepatitis B patients
- Viral load: > 2x104 IU/mL of HBV DNA
- HBeAg positive
- Increased levels of ALT and/or evidence of chronic hepatitis on liver biopsy Group C: Healthy carriers
- Viral load: not exceeding 2x103 IU/mL of HBV DNA
- HBeAg negative
- Normal levels of ALT measured at least twice, at least 3 months apart, during the last 6 months Group D: HBeAg negative chronic hepatitis B patients
- Viral load: > 2x103 IU/mL of HBV DNA
- HBeAg negative
- Increased levels of ALT and/or evidence of chronic hepatitis on liver biopsy
Exclusion Criteria:
- Any hepatitis B specific treatment prior to blood sampling at Visit 1.
- Any known clinically significant anaemia or any other condition within 7 days prior to study entry (Visit 1) as per medical records that would preclude the drawing of blood as described in the protocol.
- Receipt of live attenuated vaccines within 30 days preceding the blood sampling at Visit 1 and the administration of a pandemic influenza vaccine within 21 days preceding the blood sampling at Visit 1.
- Receipt of blood products within 120 days prior to study entry (Visit 1).
- Receipt of immunoglobulins within 120 days prior to study entry (Visit 1).
- Receipt of interferon within 120 days prior to study entry (Visit 1).
- Use of any investigational or non-registered product (drug or vaccine) within 30 days preceding study start, or planned use during the study period.
- Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).
- History of immunosuppressive or immune-mediated disorders including autoimmune diseases, human immunodeficiency virus (HIV) infection and hepatitis C infection, based on medical history and physical examination (no laboratory testing required).
- Pregnant or lactating female.
- History of malignancy (unless there has been surgical excision followed by a sufficient observation period, of at least 5 years, to give a reasonable assurance of sustained cure and which, in the estimate of the investigator, is not likely to recur during the study period).
- Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs (including chloroquine) within six months prior to the blood sampling at Visit 1 (for corticosteroids, this will mean prednisone ≥10 milligram/day (10 mg/day), or equivalent). Inhaled and topical steroids are allowed.
- History of type I or type II diabetes mellitus including cases controlled with diet alone (a subject with past gestational diabetes is eligible).
- History of major congenital defect.
- Subjects with a history of, or current, alcohol or substance abuse.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:他の
- 割り当て:非ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
他の:Immune tolerant patients Group
Immune tolerant patients aged between and including 18 and 65 years of age at study start, having high levels of hepatitis B viruss (HBV) replication characterized by elevated HBV DNA levels and presence of hepatitis B envelope antigen (HBeAg), but normal alanine aminotransferase (ALT) levels with normal or mild histology findings.
|
A single blood sample was to be taken from all subjects at the study visit.
No study-related treatment was given to the study participants.
|
他の:HBeAg positive Group
HBeAg positive chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having elevated or fluctuating ALT levels, presence of HBeAg and variable HBV DNA on a high level, histology mainly with activee inflammation and varying degrees of liver fibbrosis.
|
A single blood sample was to be taken from all subjects at the study visit.
No study-related treatment was given to the study participants.
|
他の:Inactive carriers Group
Inactive carriers aged between and including 18 and 65 years of age at study start, having normal ALT levels, undetectable or low levels of serum HBV DNA; absence of HBeAg and presence of anti-HBe antibodies, histology with little or no inflammation and varying degrees of liver fibrosis.
|
A single blood sample was to be taken from all subjects at the study visit.
No study-related treatment was given to the study participants.
|
他の:HBeAg negative Group
HBeAg negative chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having absence of HBeAg, presence of anti-HBe, elevated ALT and HBV DNA levels, histology with significant inflammatory changes, liver fibrosis and cirrhosis.
|
A single blood sample was to be taken from all subjects at the study visit.
No study-related treatment was given to the study participants.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1
時間枠:At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD4, CD45RA, ICOS, HLA-DR, PD-1 and anti-Foxp3.
|
At the time of the visit for each subject (i.e., Day 0)
|
Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1
時間枠:At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD4, CD45RA, ICOS, HLA-DR, PD-1 and anti-Foxp3.
|
At the time of the visit for each subject (i.e., Day 0)
|
Frequency of CD4+Foxp3+ Expressing CD45RA and/or Glucocorticoid-induced Tumor Necrosis Factor Receptor-related Protein (GITR) and/or Proliferation Marker Ki67
時間枠:At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD4, CD45RA, GITR, anti-Foxp3 and Ki67.
|
At the time of the visit for each subject (i.e., Day 0)
|
Frequency of CD4+Foxp3- Expressing CD45RA and/or GITR and/or Ki67
時間枠:At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD4, CD45RA, GITR, anti-Foxp3 and Ki67.
|
At the time of the visit for each subject (i.e., Day 0)
|
Frequency of CD4+Foxp3+ Expressing CD45RA and/or, Chemokine (C-C Motif) Receptor 7 (CCR7) and/or CD62L
時間枠:At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD4, CD45RA, CCR7, CD62L and anti-Foxp3.
|
At the time of the visit for each subject (i.e., Day 0)
|
Frequency of CD4+Foxp3- Expressing CD45RA and/or CCR7 and/or CD62L
時間枠:At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD4, CD45RA, CCR7, CD62L and anti-Foxp3.
|
At the time of the visit for each subject (i.e., Day 0)
|
Frequency of CD4+Foxp3+ Expressing CD45RA and/or CD39 and/or Tumor Necrosis Factor Receptor 2 (TNFR2)
時間枠:At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD4, CD45RA, CD39, TNFR2 and anti-Foxp3.
|
At the time of the visit for each subject (i.e., Day 0)
|
Frequency of CD4+Foxp3- Expressing CD45RA and/or CD39 and/or TNFR2
時間枠:At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD4, CD45RA, CD39, TNFR2 and anti-Foxp3.
|
At the time of the visit for each subject (i.e., Day 0)
|
Frequency of CD4+Foxp3+ Expressing CD45RA and/or CTLA4 and/or OX40
時間枠:At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD4, CD45RA, CTLA4, OX40 and anti-Foxp3.
|
At the time of the visit for each subject (i.e., Day 0)
|
Frequency of CD4+Foxp3- Expressing CD45RA and/or CTLA4 and/or OX40
時間枠:At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD4, CD45RA, CTLA4, OX40 and anti-Foxp3.
|
At the time of the visit for each subject (i.e., Day 0)
|
Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples
時間枠:At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD4, CD69, LAP and anti-Foxp3.
|
At the time of the visit for each subject (i.e., Day 0)
|
Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples
時間枠:At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD4, CD69, LAP and anti-Foxp3.
|
At the time of the visit for each subject (i.e., Day 0)
|
Frequency of HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Frozen Samples
時間枠:At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD4, CD69, LAP and anti-Foxp3.
|
At the time of the visit for each subject (i.e., Day 0)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples
時間枠:At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD4, CD40-L, IFNg, IL-2 and IL-17. Note: The precision of the measure (i.e., four decimals) of median and inter-quartile range is not sufficient to distinguish between the values median, lower and upper limits of inter-quartile range for some of the data presented within the table below (e.g., median=0.0001 and inter-quartile range=0.0001 to 0.0001). |
At the time of the visit for each subject (i.e., Day 0)
|
Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples
時間枠:At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD8, CD40-L, IFNg, IL-2 and IL-17. Note: The precision of the measure (i.e., four decimals) of median and inter-quartile range is not sufficient to distinguish between the values median, lower and upper limits of inter-quartile range for some of the data presented within the table below (e.g., median=0.0001 and inter-quartile range=0.0001 to 0.0001). |
At the time of the visit for each subject (i.e., Day 0)
|
Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples
時間枠:At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD4, CD40-L, IFNg, IL-2 and IL-17. Note: The precision of the measure (i.e., four decimals) of median and inter-quartile range is not sufficient to distinguish between the values median, lower and upper limits of inter-quartile range for some of the data presented within the table below (e.g., median=0.0001 and inter-quartile range=0.0001 to 0.0001). |
At the time of the visit for each subject (i.e., Day 0)
|
Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples
時間枠:At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD8, CD40L, IFNg, IL-2 and IL-17. Note: The precision of the measure (i.e., four decimals) of median and inter-quartile range is not sufficient to distinguish between the values median, lower and upper limits of inter-quartile range for some of the data presented within the table below (e.g., median=0.0001 and inter-quartile range=0.0001 to 0.0001). |
At the time of the visit for each subject (i.e., Day 0)
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 113854
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
Blood withdrawalの臨床試験
-
University of UtahAlbert Einstein College of Medicine; University of California, San Francisco; National Human Genome... と他の協力者完了新生児スクリーニング
-
Ischemia Care LLC完了虚血性脳卒中 | 心房細動 | 血栓性脳卒中 | 一過性脳虚血発作 | 心塞栓性脳卒中 | 脳底動脈の脳卒中 | 一過性脳血管イベントアメリカ
-
Applied Science & Performance Institute完了
-
Bedford Hospital NHS TrustAnglia Ruskin Universityわからない